



George Lasezkay and Bernard Chauvin join Novagali Pharma Supervisory Board

**These two nominations confirms Novagali's willingness
to become a major actor in Ophthalmology**

Evry, France, December 5, 2005 - Novagali Pharma, a biopharmaceutical company specialized in ophthalmology, announces today the appointment of George Lasezkay and Bernard Chauvin to the Supervisory Board, two esteemed figures of the pharmaceutical and eye care business.

"The participation of both George Lasezkay and Dr. Bernard Chauvin is a key asset for Novagali Pharma" said Jerome Martinez, President and CEO, who enthusiastically added, "their combined expertise will strengthen our know how in ophthalmology in terms of development and marketing of innovative products".

"Their relationship with the main ophthalmic companies in Europe and USA will allow us to speed up ongoing negotiations and to initiate new partnerships to get our products marketed in both territories" said Mr Martinez.

Dr. George Lasezkay earned B.S. Pharmacy, Doctor of Pharmacy and J.D. degrees. He has more than twenty years of experience in the US pharmaceutical industry. Former Corporate Vice President of Corporate Development at Allergan, his unique track records counts over 60 acquisition, alliance and licensing operations mainly in ophthalmology. He currently serves as Director of Valentis Inc., Collagenex Pharmaceuticals, Acuity Pharmaceuticals, and Sucampo Pharmaceuticals.

Dr. Bernard Chauvin, Ophthalmologist, headed Laboratoires Chauvin for 18 years prior to joining Neurotech, a biotech company specialized in back of the eye, as CEO. Dr. Bernard Chauvin has a significant expertise regarding pharmaceutical development and marketing of ophthalmic products.

"When I first was presented the company, I immediately found the rationale of cationic emulsions very attractive, especially when applied to ophthalmology. It really is a breakthrough approach to treat major ocular diseases" declared Dr. Lasezkay. "In ophthalmology there is a huge medical need for products providing efficacy and comfort for the patients. Novagali's products are designed to meet these requirements, and their pipeline is highly relevant to these needs".

According to Dr. Bernard Chauvin, "Novagali's technology platform is really bright and paves the way to new therapeutic perspectives in ophthalmology". He specified "the team is qualified, dynamic, ready to take up challenges. Their choice to focus on ophthalmic products already allowed them to acquire a great deal of expertise in a field still not very competing. The result is convincing, several products are at phase II clinical stage and phases III trials are planned for 2006".

About Novagali Pharma: <http://www.novagali.com>

Novagali Pharma, a biopharmaceutical company specialized in ophthalmology, develops innovative treatments for the all the eye segments.

Founded in 2000, the firm has raised 18 million Euros from 1.2.3. Multinova, Auriga Partners, CDC Entreprises Innovation, Fonds de co-investissement J.E., Rothschild Investment Partners, Siparex Ventures et Crédit Agricole Private Equity.

Press Contact: Genevieve Garrigos
genevieve.garrigos@novagali.com